Rigel Appoints Board Member Alison L. Hannah, M.D. as Chief Medical Officer
Rigel Pharmaceuticals appointed Alison L. Hannah, M.D. as Executive Vice President and Chief Medical Officer, succeeding Lisa Rojkjaer, M.D. Hannah, a board member since 2021, resigned from the board to assume the executive role.
Key figures
- Drug Name
- R289
- Phase Of Trial
- Phase 1b
- Board tenure years
- since 2021
- Regulatory applications filed
- over 40
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.